322 related articles for article (PubMed ID: 27078712)
1. NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive.
Pavel M; Jann H; Prasad V; Drozdov I; Modlin IM; Kidd M
Neuroendocrinology; 2017; 104(2):170-182. PubMed ID: 27078712
[TBL] [Abstract][Full Text] [Related]
2. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
[TBL] [Abstract][Full Text] [Related]
3. Blood Molecular Genomic Analysis Predicts the Disease Course of Gastroenteropancreatic Neuroendocrine Tumor Patients: A Validation Study of the Predictive Value of the NETest®.
van Treijen MJC; van der Zee D; Heeres BC; Staal FCR; Vriens MR; Saveur LJ; Verbeek WHM; Korse CM; Maas M; Valk GD; Tesselaar MET
Neuroendocrinology; 2021; 111(6):586-598. PubMed ID: 32492680
[TBL] [Abstract][Full Text] [Related]
4. Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy.
Ćwikła JB; Bodei L; Kolasinska-Ćwikła A; Sankowski A; Modlin IM; Kidd M
J Clin Endocrinol Metab; 2015 Nov; 100(11):E1437-45. PubMed ID: 26348352
[TBL] [Abstract][Full Text] [Related]
5. Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience.
Malczewska A; Witkowska M; Wójcik-Giertuga M; Kuśnierz K; Bocian A; Walter A; Rydel M; Robek A; Pierzchała S; Malczewska M; Leś-Zielińska I; Czyżewski D; Ziora D; Pilch-Kowalczyk J; Zajęcki W; Kos-Kudła B
Neuroendocrinology; 2021; 111(4):304-319. PubMed ID: 32335553
[TBL] [Abstract][Full Text] [Related]
6. Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies.
Modlin IM; Frilling A; Salem RR; Alaimo D; Drymousis P; Wasan HS; Callahan S; Faiz O; Weng L; Teixeira N; Bodei L; Drozdov I; Kidd M
Surgery; 2016 Jan; 159(1):336-47. PubMed ID: 26456125
[TBL] [Abstract][Full Text] [Related]
7. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.
Bodei L; Kidd M; Modlin IM; Severi S; Drozdov I; Nicolini S; Kwekkeboom DJ; Krenning EP; Baum RP; Paganelli G
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):839-851. PubMed ID: 26596723
[TBL] [Abstract][Full Text] [Related]
8. Assessment of NETest Clinical Utility in a U.S. Registry-Based Study.
Liu E; Paulson S; Gulati A; Freudman J; Grosh W; Kafer S; Wickremesinghe PC; Salem RR; Bodei L
Oncologist; 2019 Jun; 24(6):783-790. PubMed ID: 30158287
[TBL] [Abstract][Full Text] [Related]
9. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
[TBL] [Abstract][Full Text] [Related]
10. Measurement of circulating transcript levels (NETest) to detect disease recurrence and improve follow-up after curative surgical resection of well-differentiated pancreatic neuroendocrine tumors.
Genç CG; Jilesen APJ; Nieveen van Dijkum EJM; Klümpen HJ; van Eijck CHJ; Drozdov I; Malczewska A; Kidd M; Modlin I
J Surg Oncol; 2018 Jul; 118(1):37-48. PubMed ID: 30114319
[TBL] [Abstract][Full Text] [Related]
11. A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility.
Modlin IM; Kidd M; Falconi M; Filosso PL; Frilling A; Malczewska A; Toumpanakis C; Valk G; Pacak K; Bodei L; Öberg KE
Ann Oncol; 2021 Nov; 32(11):1425-1433. PubMed ID: 34390828
[TBL] [Abstract][Full Text] [Related]
12. [Advances of circulating biomarkers in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Mar; 20(3):357-360. PubMed ID: 28338171
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity and Specificity of the NETest: A Validation Study.
Al-Toubah T; Cives M; Valone T; Blue K; Strosberg J
Neuroendocrinology; 2021; 111(6):580-585. PubMed ID: 32615553
[TBL] [Abstract][Full Text] [Related]
14. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
Modlin IM; Drozdov I; Alaimo D; Callahan S; Teixiera N; Bodei L; Kidd M
Endocr Relat Cancer; 2014 Aug; 21(4):615-28. PubMed ID: 25015994
[TBL] [Abstract][Full Text] [Related]
15. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina.
Belli SH; Oneto A; Aranda C; O'Connor JM; Domenichini E; Roca E; Méndez G; Bestani MC; Parma P; Giacomi N; Marmissolle F
Acta Gastroenterol Latinoam; 2009 Sep; 39(3):184-9. PubMed ID: 19845257
[TBL] [Abstract][Full Text] [Related]
16. The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection and disease progression.
Filosso PL; Kidd M; Roffinella M; Lewczuk A; Chung KM; Kolasinska-Cwikla A; Cwikla J; Lowczak A; Doboszynska A; Malczewska A; Catalano M; Zunino V; Boita M; Arvat E; Cristofori R; Guerrera F; Oliaro A; Tesselaar M; Buikhuisen W; Kos-Kudla B; Papotti M; Bodei L; Drozdov I; Modlin I
Eur J Cardiothorac Surg; 2018 Mar; 53(3):631-639. PubMed ID: 29145657
[TBL] [Abstract][Full Text] [Related]
17. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors].
Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L
Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832
[TBL] [Abstract][Full Text] [Related]
18. Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy of
Bodei L; Raj N; Do RK; Mauguen A; Krebs S; Reidy-Lagunes D; Schöder H
J Nucl Med; 2023 Apr; 64(4):567-573. PubMed ID: 36396457
[TBL] [Abstract][Full Text] [Related]
19. Placental growth factor supports neuroendocrine tumor growth and predicts disease prognosis in patients.
Hilfenhaus G; Göhrig A; Pape UF; Neumann T; Jann H; Zdunek D; Hess G; Stassen JM; Wiedenmann B; Detjen K; Pavel M; Fischer C
Endocr Relat Cancer; 2013 Jun; 20(3):305-19. PubMed ID: 23463017
[TBL] [Abstract][Full Text] [Related]
20. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest.
Bodei L; Kidd MS; Singh A; van der Zwan WA; Severi S; Drozdov IA; Malczewska A; Baum RP; Kwekkeboom DJ; Paganelli G; Krenning EP; Modlin IM
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):895-906. PubMed ID: 31838581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]